Impact of Age and Comorbid Conditions on Incidence Rates of COVID‐19‐Associated Hospitalizations, 2020–2021
Open Access
- 17 November 2024
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (11) , e70016
Abstract
Background: COVID‐19‐associated hospitalization rates by age and comorbid conditions can more precisely assess risk for severe illness and target prevention and treatment strategies.Methods: We performed a retrospective study to estimate population‐based COVID‐19‐associated hospitalization among patients by age and selected comorbid conditions in three hospital systems in Rochester and New York City (NYC), NY. Incidence rate ratios (IRR) comparing incidence rates for patients with and without these comorbidities were determined.Results: From March 2020 to December 2021, 7779 patients were hospitalized with COVID‐19 of whom 43.8% had ≥3 comorbid conditions. Overall annual incidence ranged from 325.3 to 965.8 per 100,000 persons. Age group‐specific incidence was lowest in children 10–14 years (range 4.4–58.9) and highest in adults ≥85 years (range 2790.5–5889.6). Incidence rates for comorbid conditions generally increased with increasing age while IRR decreased with increasing age. Children in NYC 5–17 years with asthma or obesity had 3.4 and 53.3 times higher hospitalization rates, respectively, than children without these conditions. Adults in all age groups with obesity, diabetes, coronary artery disease, or congestive heart failure CHF had 1.6–4.7 times, 1.7–7.2 times, 2.0–10.1 times, or 1.7–20.2 times higher hospitalization rates, respectively, than those without these conditions. Adults ≥50 years with asthma had 1.5 to 1.8 times higher hospitalization rates than those without asthma.Conclusions: The burden of hospitalization with COVID‐19 was high, particularly among adults ≥85 years and adults with obesity, diabetes, CAD, or CHF. However, the impact of comorbidities was less in older adults. Population‐based incidence rates by age and comorbidities provide more precise estimates of the benefits of vaccines and antiviral medications.Keywords
Funding Information
- Merck Sharp and Dohme United Kingdom
This publication has 17 references indexed in Scilit:
- Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020Clinical Infectious Diseases, 2021
- Prevalence of SARS-CoV-2 Antibodies in New York City Adults, June–October 2020: A Population-Based SurveyThe Journal of Infectious Diseases, 2021
- Obesity as a Risk Factor for Severe COVID-19 and Complications: A ReviewCells, 2021
- Mortality Among US Patients Hospitalized With SARS-CoV-2 Infection in 2020JAMA Network Open, 2021
- Repeated cross-sectional sero-monitoring of SARS-CoV-2 in New York CityNature, 2020
- Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart AssociationCirculation, 2020
- Continued Decline in Obesity and Severe Obesity Prevalence Among New York City Public School Youth in Grades K‐8: 2011‐2017Obesity, 2020
- Risk of Severe Influenza Among Adults With Chronic Medical ConditionsThe Journal of Infectious Diseases, 2019
- Human mobility and the spatial transmission of influenza in the United StatesPLOS Computational Biology, 2017
- Epidemiological evidence of an early wave of the 1918 influenza pandemic in New York CityProceedings of the National Academy of Sciences, 2005